



**Research Article**

**FORMULATION DEVELOPMENT OF EFAVIRENZ TABLETS EMPLOYING  $\beta$  CYCLODEXTRIN- POLOXAMER 407- PVP K30 BY DIRECT COMPRESSION METHOD**

**Sanjit Singh Lamba<sup>1</sup>, K.P.R. Chowdary<sup>1,2\*</sup> and P. Suresh<sup>3</sup>**

<sup>1</sup>Eisai Knowledge Center, Eisai Pharmatechnology and Manufacturing Pvt., Ltd., Ramky Pharma City (SEZ), Parawada, Visakhapatnam

<sup>2</sup>Former Principal, A. U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam.

<sup>3</sup>GITAM Institute of Pharmacy, GITAM University, Visakhapatnam

(Received: 10 December, 2012; Accepted: 20 December, 2012, 2013; Published: 29 December, 2012)

**Corresponding Author's email:** [prof.kprchowdary@rediffmail.com](mailto:prof.kprchowdary@rediffmail.com)

**Abstract:** Efavirenz, a widely prescribed anti retroviral drug belongs to class II under BCS and exhibit low and variable oral bioavailability due to its poor aqueous solubility. Its oral absorption is dissolution rate limited and it requires enhancement in the solubility and dissolution rate for increasing its oral bioavailability. The objective of the study is to evaluate the feasibility of formulating efavirenz  $\beta$ CD- Poloxamer 407 /PVP K30 inclusion complexes into tablets by direct compression method and to evaluate the effects of  $\beta$ CD, Poloxamer 407 and PVP K30 on the dissolution rate and dissolution efficiency of efavirenz tablets in 2<sup>3</sup> factorial study. Drug –  $\beta$ CD- Poloxamer 407 / PVP K30 inclusion complexes were prepared by kneading method. Tablets each containing 100 mg of efavirenz were prepared by direct compression method employing various  $\beta$ CD complexes as per 2<sup>3</sup> factorial design and the tablets were evaluated for dissolution rate and other physical properties. Efavirenz –  $\beta$ CD- Poloxamer 407 and efavirenz  $\beta$ CD –PVP K30 inclusion complexes could be formulated into compressed tablets by direct compression method. The tablets formulated employing drug-  $\beta$ CD- Poloxamer 407/ PVP K30 inclusion complexes disintegrated rapidly within 8 sec – 2 min. 50 sec. Efavirenz dissolution was rapid and higher from the tablets formulated employing drug-  $\beta$ CD- Poloxamer 407/ PVP K30 inclusion complexes when compared to the tablets containing efavirenz alone. The tablets formulated employing drug-  $\beta$ CD- Poloxamer 407/ PVP K30 inclusion complexes fulfilled the official (I.P 2010) dissolution rate test specification of NLT 70 % in 30 min prescribed for efavirenz tablets. The individual as well as combined effects of the three factors involved i.e.,  $\beta$ CD ( factor A), Poloxamer 407 ( factor B) and PVP K30 ( factor C) were highly significant (P< 0.01) in enhancing the dissolution rate (K<sub>1</sub>) and dissolution efficiency (DE<sub>30</sub>) of efavirenz. Among the three factors Poloxamer 407 (factor B) gave highest enhancement in the dissolution rate (K<sub>1</sub>) and dissolution efficiency (DE<sub>30</sub>) of efavirenz tablets.  $\beta$ CD alone gave low dissolution rates. Combination of  $\beta$ CD with Poloxamer 407 or PVP K30 gave a significantly higher dissolution rate (K<sub>1</sub>) of efavirenz. Hence Poloxamer 407 alone or a combination of  $\beta$ CD with either Poloxamer 407 or PVP K30 is recommended to enhance the dissolution rate and efficiency of efavirenz tablets.

**Keywords:** Efavirenz Tablets,  $\beta$  Cyclodextrin, Poloxamer 407, PVP K30, Dissolution Rate, Direct Compression

**INTRODUCTION**

Efavirenz, a widely prescribed HIV- 1 specific non – nucleoside reverse transcriptase inhibitor drug belongs to class II under BCS and exhibit low and variable oral bioavailability due to its poor aqueous solubility. It is practically insoluble in water and aqueous fluids. As such its oral absorption is dissolution rate limited and it requires enhancement in solubility and dissolution rate for increasing its oral bioavailability. Several techniques<sup>1</sup> such as micronization, cyclodextrin complexation, use of surfactants and solubilizers, solid dispersion in water soluble and dispersible carriers, use of salts, prodrugs and polymorphs which exhibit high solubility, micro emulsions and self emulsifying micro and nano disperse systems have been used to enhance the solubility, dissolution rate and bioavailability of poorly soluble drugs. Among the various approaches complexation with cyclodextrins<sup>2-5</sup> and use of Poloxamer 407 (surfactant)<sup>6-8</sup> and PVP<sup>9,10</sup> have gained good acceptance in recent years in industry for enhancing the solubility and dissolution rate of poorly soluble drugs.

We have reported<sup>11</sup> earlier that combination of  $\beta$  – cyclodextrin ( $\beta$ CD) with Poloxamer 407 and/or PVP K30 has markedly enhanced the solubility and dissolution rate of efavirenz, a BCS class II drug than is possible with them individually. The objective of the present study is to evaluate the feasibility of formulating efavirenz –  $\beta$ CD- Poloxamer 407 and efavirenz  $\beta$ CD –PVP K30 inclusion complexes into tablets by direct compression method and to study the effects of  $\beta$ CD, Poloxamer 407 and PVP K30 on the dissolution rate of efavirenz tablets in a 2<sup>3</sup> factorial study.

**EXPERIMENTAL**

**Materials**

Efavirenz was a gift sample from M/s. Eisai Pharmatechnology and Manufacturing Pvt. Ltd., Visakhapatnam.  $\beta$  Cyclodextrin was gift sample from M/s. Cerestar Inc., USA. Methanol (Qualigens), poly vinyl pyrrolidone (PVP K30) and Poloxamer 407 were procured from commercial sources. All other materials used were of pharmacopoeial grade.

## Methods

### Estimation of Efavirenz

A UV Spectrophotometric method based on the measurement of absorbance at 245 nm in water containing 2 % Sodium lauryl sulphate (SLS) was used for the estimation of efavirenz. The method was validated for linearity, accuracy, precision and interference. The method obeyed Beer's law in the concentration range of 0-10 µg/ml. When a standard drug solution was repeatedly assayed (n=6), the relative error and coefficient of variance were found to be 0.85% and 1.20 % respectively. No interference by the excipients used in the study was observed.

### Preparation of efavirenz- βCD- Poloxamer 407/ PVP K30 complexes

Solid inclusion complexes of efavirenz, βCD, Poloxamer 407 and PVP K30 were prepared as per 2<sup>3</sup> – factorial study by kneading method. Efavirenz, βCD, Poloxamer 407 and

PVP K30 were triturated in a mortar with a small volume of solvent consisting of a blend of water: methanol (1:1). The thick slurry formed was kneaded for 45 min and then dried at 55°C until dry. The dried mass was powdered and sieved to mesh No. 120.

### Preparation of Efavirenz- βCD - Poloxamer 407/ PVP K30 tablets

Compressed tablets each containing 100 mg of efavirenz were prepared as per 2<sup>3</sup> – factorial study by direct compression method employing Efavirenz- βCD - Poloxamer 407/ PVP K30 inclusion complexes as per the formulae given in Table 1. All the materials required as per the formulae were blended in a closed polyethylene bag. The blends were directly compressed into tablets on a 16-station tablet punching machine (M/s Cadmach machineries Pvt. Ltd., Ahmedabad) to a hardness of 5- 6 kg/cm<sup>2</sup> using 9 mm flat punches. In each case 100 tablets were compressed.

**Table 1: Formulae of Efavirenz Tablets Prepared by Direct Compression Method Employing Drug- βCD – Poloxamer 407- PVP K30 Inclusion Complexes as per 2<sup>3</sup> Factorial Study**

Ingredient (mg / tablet)	Efavirenz Tablet Formulation							
	T <sub>1</sub>	T <sub>a</sub>	T <sub>b</sub>	T <sub>ab</sub>	T <sub>c</sub>	T <sub>ac</sub>	T <sub>bc</sub>	T <sub>abc</sub>
Efavirenz (1)**	100	-	-	-	-	-	-	-
EF- βCD (1:2) (a)	-	300	-	-	-	-	-	-
EF - P 407(2%) (b)	-	-	102	-	-	-	-	-
EF - βCD (1:2) - P 407(2%) (ab)	-	-	-	306	-	-	-	-
EF - PVP K30 (2%) (c)	-	-	-	-	102	-	-	-
EF - βCD (1:2) - PVP K30 (2%) (ac)	-	-	-	-	-	306	-	-
EF - P 407(2%) - PVP K30 (2%) (bc)	-	-	-	-	-	-	104	-
EF - βCD (1:2) - P 407 (2%) - PVP K30 (2%) (abc)	-	-	-	-	-	-	-	312
Crospovidone	11	18	11	18	11	18	11	18
Talc	4.4	7.0	4.4	7.0	4.4	7.0	4.4	7.0
Magnesium Stearate	4.4	7.0	4.4	7.0	4.4	7.0	4.4	7.0
Lactose	100.2	28	98.2	22	98.2	22	96.2	16
Total weight (mg)	220	360	220	360	220	360	220	360

EF: Efavirenz; βCD: β cyclodextrin; P 407: Poloxamer 407; PVP K30: poly vinyl pyrrolidone K30; \*\* Figures in parentheses are codes as per 2<sup>3</sup> Factorial Design

### Evaluation of tablets:

Hardness of the tablets was tested using a Monsanto hardness tester. Friability of the tablets was determined in a Roche friabilator. Disintegration time of the tablets prepared was determined using a Thermonic tablet disintegration test machine using water as test fluid.

### Dissolution rate study:

The dissolution rate of efavirenz from the tablets prepared was studied in 900 ml water containing 2 % Sodium lauryl sulphate (SLS) using Disso 2000 (Labindia) 8-station dissolution test apparatus with a paddle stirrer at 50 rpm. A temperature 37±1°C was maintained throughout the study. One tablet containing 100 mg of efavirenz was used in each test. Samples of dissolution media (5 ml) were withdrawn through a filter (0.45 µ) at different intervals of time, suitable diluted and assayed for efavirenz at 245 nm. The sample of dissolution fluid withdrawn at each time was

replaced with fresh fluid. The dissolution experiments were replicated three times each (n=3).

### Analysis of results:

Dissolution data were subjected to analysis as per zero order and first order kinetics and the corresponding dissolution rates were calculated. Dissolution efficiency (DE<sub>30</sub>) values were calculated as suggested by Khan<sup>12</sup>.

## RESULTS AND DISCUSSION

The feasibility of formulating efavirenz- βCD - Poloxamer 407/ PVP K30 solid inclusion complexes into tablets was evaluated by preparing efavirenz tablets employing the solid inclusion complexes by direct compression method. To evaluate the individual and combined effects of βCD, Poloxamer 407 and PVP K30 on the dissolution rate and efficiency of efavirenz tablets, tablets each containing 100 mg of efavirenz were formulated employing solid inclusion complexes of drug- βCD - Poloxamer 407/ PVP K30 as per

$2^3$  factorial design. For this purpose two levels of  $\beta$ CD (0 and 1: 2 ratio of Drug :  $\beta$ CD) and two levels of each of Poloxamer 407 and PVP K30 (0 and 2%) were selected and the corresponding eight treatments involved in the formulation of tablets as per  $2^3$ -factorial study were efavirenz pure drug (1); EF-  $\beta$ CD (1:2) inclusion binary complex (a); EF - Poloxamer 407 (2%) binary mixture (b);

EF -  $\beta$ CD (1:2) – Poloxamer 407 (2%) ternary complex (ab); EF – PVP K30 (2%) binary mixture (c); EF -  $\beta$ CD (1:2) – PVP K30 (2%) ternary complex (ac); EF – Poloxamer 407 (2%) - PVP K30 (2%) ternary complex (bc); EF -  $\beta$ CD (1:2)- Poloxamer 407 (2%) - PVP K30 (2%) inclusion complex (abc).

**Table 2: Physical Properties of Efavirenz Tablets Prepared Employing Drug- $\beta$ CD – Poloxamer 407/ PVP K30 by Direct Compression Method as per  $2^3$  Factorial Study**


Formulation code as per $2^3$ factorial design	Hardness (Kg/sq. cm)	Friability (% weight loss)	DT (min-sec)	Drug Content (mg/tablet)
T <sub>1</sub>	5.0	0.92	0-10	99.2
T <sub>a</sub>	6.0	0.80	1-10	99.3
T <sub>b</sub>	6.5	0.81	0-08	101.4
T <sub>ab</sub>	5.5	0.76	1-25	101.3
T <sub>c</sub>	5.0	0.51	2-20	102.6
T <sub>ac</sub>	6.0	0.79	2-50	101.7
T <sub>bc</sub>	6.5	0.82	0-20	99.3
T <sub>abc</sub>	5.0	0.61	2-30	98.9

All the prepared tablets were evaluated for drug content, hardness, friability and disintegration time and dissolution rate of efavirenz. The physical properties of the tablets prepared are given in Table 2. The dissolution profiles of

various tablets formulated are shown in Fig. 1. The dissolution parameters of the tablets prepared are summarized in Table 3.

**Table 3: Dissolution Parameters of Efavirenz Tablets Prepared as per  $2^3$  Factorial Study Employing Drug- $\beta$ CD- Poloxamer 407/ PVP K30 Inclusion Complexes**

Formulation code as per $2^3$ factorial design	Direct Compression Method			
	T <sub>50</sub> (min)	Dissolution Rate (K <sub>1</sub> x 10 <sup>2</sup> ) (min <sup>-1</sup> ) ( $\bar{x}$ ) (cv)	Increase in K <sub>1</sub> (no. of folds)	Dissolution Efficiency (DE <sub>30</sub> ) (%) ( $\bar{x}$ ) (cv)
T <sub>1</sub>	20	1.53(1.1)	-	43.1(1.5)
T <sub>a</sub>	4	6.14(0.8)	4.01	74.5(1.8)
T <sub>b</sub>	3	11.50(0.7)	7.64	79.4(1.6)
T <sub>ab</sub>	3	7.92(0.6)	5.17	76.9(1.1)
T <sub>c</sub>	4	8.46(1.2)	5.53	78.9(0.8)
T <sub>ac</sub>	3	6.52(1.4)	4.26	79.8(0.6)
T <sub>bc</sub>	3	8.65(1.2)	5.65	84.3(1.2)
T <sub>abc</sub>	4	6.62(1.6)	4.32	76.6(1.4)



**Fig. 1: Dissolution Profiles of Efavirenz Tablets Formulated Employing  $\beta$ CD, Poloxamer 407 and PVP K30 by Direct Compression Method as per  $2^3$  Factorial Design**

All the tablets prepared were found to contain efavirenz within  $100 \pm 5\%$  of the labeled claim. Hardness of the tablets was in the range  $5.0 - 6.5 \text{ Kg/cm}^2$ . Percentage weight loss in the friability test was less than  $0.92\%$  in all the cases. Plain tablets formulated employing efavirenz alone disintegrated rapidly within 10 sec. Tablets prepared by direct compression method employing  $\beta$ CD– Poloxamer 407/ PVP K30 inclusion complexes also disintegrated rapidly and the disintegration times of these tablets were in the range 8 sec to 2 min.50 sec. All the tablets prepared by direct compression method employing  $\beta$ CD– Poloxamer 407/ PVP K30 inclusion complexes fulfilled all the official (I.P) specification of uncoated tablets with regard to drug content, hardness, friability and disintegration time.

The dissolution rate of efavirenz from the tablets prepared was studied in 900 ml of water containing 2 % SLS as prescribed in I.P 2010. Dissolution of efavirenz from all the tablets prepared followed first order kinetics with the correlation coefficient ( $r$ ) values above 0.970. Efavirenz dissolution was rapid and higher from the tablets formulated employing drug-  $\beta$ CD- Poloxamer 407/ PVP K30 inclusion complexes when compared to the tablets containing efavirenz alone. Dissolution parameters,  $K_1$  and  $DE_{30}$  were subjected to ANOVA to find out the significance of the individual and combined effects of the three factors ( $\beta$ CD, Poloxamer 407, PVP K30) in enhancing the dissolution rate and efficiency of efavirenz tablets. The individual as well as combined effects of the three factors involved i.e.,  $\beta$ CD (factor A), Poloxamer 407 ( factor B) and PVP K30 ( factor C) were highly significant ( $P < 0.01$ ) in enhancing the dissolution rate ( $K_1$ ) and dissolution efficiency ( $DE_{30}$ ) of efavirenz. Among the three factors Poloxamer 407 (factor B) gave highest enhancement in the dissolution rate ( $K_1$ ) and dissolution efficiency ( $DE_{30}$ ) of efavirenz tablets.  $\beta$ CD alone gave a dissolution rate ( $K_1$ ) of  $6.14 \times 10^{-2} \text{ min}^{-1}$ . Whereas  $\beta$ CD in combination with Poloxamer 407 and PVP K30 gave a dissolution rate ( $K_1$ ) of  $7.92 \times 10^{-2}$  and  $6.52 \times 10^{-2} \text{ min}^{-1}$  respectively. Thus combination of  $\beta$ CD with

Poloxamer 407 or PVP K30 gave a significantly higher dissolution rate ( $K_1$ ) of efavirenz.

I.P 2010 prescribed a dissolution rate specification of NLT 70% in 30 min for efavirenz tablets. All the efavirenz tablets formulated employing drug-  $\beta$ CD - Poloxamer 407 / PVP K30 inclusion complexes fulfilled the official (I.P) dissolution rate specification of efavirenz tablets. Whereas plain tablets formulated employing efavirenz alone did not fulfill the official dissolution rate specification. Hence Poloxamer 407 alone or a combination of  $\beta$ CD with either Poloxamer 407 or PVP K30 is recommended to enhance the dissolution rate and dissolution efficiency of efavirenz tablets.

## CONCLUSIONS

- Efavirenz –  $\beta$ CD– Poloxamer 407 and efavirenz – $\beta$ CD –PVP K30 inclusion complexes could be formulated into compressed tablets by direct compression method.
- The tablets formulated employing drug-  $\beta$ CD- Poloxamer 407/ PVP K30 inclusion complexes disintegrated rapidly within 8 sec – 2 min. 50 sec.
- Efavirenz dissolution was rapid and higher from the tablets formulated employing drug- $\beta$ CD- Poloxamer 407/ PVP K30 inclusion complexes when compared to the tablets containing efavirenz alone.
- The tablets formulated employing drug-  $\beta$ CD- Poloxamer 407/ PVP K30 inclusion complexes fulfilled the official (I.P 2010) dissolution rate test specification of NLT 70 % in 30 min prescribed for efavirenz tablets.
- The individual as well as combined effects of the three factors involved i.e.,  $\beta$ CD ( factor A), Poloxamer 407 ( factor B) and PVP K30 ( factor C) were highly significant ( $P < 0.01$ ) in

enhancing the dissolution rate ( $K_1$ ) and dissolution efficiency ( $DE_{30}$ ) of efavirenz.

- Among the three factors Poloxamer 407 (factor B) gave highest enhancement in the dissolution rate ( $K_1$ ) and dissolution efficiency ( $DE_{30}$ ) of efavirenz tablets.
- $\beta$ CD alone gave low dissolution rates. Combination of  $\beta$ CD with Poloxamer 407 or PVP K30 gave a significantly higher dissolution rate ( $K_1$ ) of efavirenz.
- Hence Poloxamer 407 alone or a combination of  $\beta$ CD with either Poloxamer 407 or PVP K30 is recommended to enhance the dissolution rate and efficiency of efavirenz tablets.

## REFERENCES

1. Chowdary, K. P. R and Madhavi, BLR, Novel Drug Delivery Technologies for Insoluble Drugs, *Indian Drugs*, **2005**; 42 (9):557 – 562.
2. Fromming, K.H. and Szejtli, J. Cyclodextrins in Pharmacy. Kluwer Academic Publications, Dordrecghi, **1994**, p 20.
3. Duchene, D., Woussidjewe, D. and Dumitriu, S. Polysaccharides in Medical Applications. Marcel Dekker, New York, **1996**, 575- 602.
4. Thompson, D.O. Crit Rev Therapeutic Drug Carrier System. **1997**, 14 (1), 1-104.
5. Hedges, A.R. Chemical Review. **1998**, 98, 2035-2044.
6. Patel, T.B., Patel, L.D., Patel, T.B., Makwana, S.H. and Patel, T.R., *International Journal of Pharmacy and Pharmaceutical Sciences*. **2010**, 2, 138- 141.
7. Pore, Y., Vyas, V., Sancheti, P., Karekar, P. and Shah, M., *Acta Pharm* **2009**; 59(4): 453-461.
8. Dumortier, G., Grossiord, J.L., Agnely, F. and Chaumeil, J.C., *Pharmaceutical Research* **2006**, 23 (12):2709-2728.
9. Giri, T. K., Badwaik, H., Alexander, A., and Tripathi, D. K., *Int. J. Applied Biology and Pharmaceutical Tech.*, **2010**;1 (2): 793- 800.
10. Aejaz, A., Jafar, M. Dehghan, M. H. G., and Adil Shareef, S., *Int. J. Pharm. and Pharmaceutical Sci.*, **2010**; 2 (1), 182- 190.
11. Sanjit Singh Lamba, KPR Chowdary and P Suresh; *Journal of Global Trends in Pharmaceutical Sci.*, **2012**; 3( 4):923-928.
12. Khan, K.A., Journal of Pharmacy and Pharmacology. **1975**, 27, 48-49.